Nasdaq:US$16.90 (-0.82) | HKEX:HK$26.35 (-0.85) | AIM:£2.49 (-0.03)
搜索
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors